reports
Hybridan Small Cap Feast - 21 November 2024
* A corporate client of Hybridan LLP ** Potential means Intention to Float (ITF) has been announced, or it is a rumour ***Arranged by type of listing and date of announcement ****Alphabetically arranged Share prices and market capitalisations taken from the current price on the day of publication Dish of the day Admissions: None Delistings: None What’s baking in the oven? Reverse Takeover: 18 November 2024: Greatland Gold (GGP.L) has entered into an agreement with certain subsidiaries of Newmont...
- Martin Hall
Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Pro...
Shield is a commercial-stage pharma company delivering specialty products that address the needs of patients with iron deficiency (ID). Since its July 2021 US launch, Shield and Viatris have increased physician awareness of the differentiating characteristics of ACCRUFeR® as an oral ID drug, in order to generate sales traction. The 3Q’24 trading update reiterated the interim statement dialog: sales continue to progress, while costs are being actively managed. Shield is being proactive, extending...
Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Pro...
Hardman & Co Research Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven 21-Nov-2024 / 11:15 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven Shield is a commercial-stage pharma company delivering specialty products that address the needs of patients with iron deficiency (ID). Since its July 2021 US launch, Shield and Viatris have increased physician awareness of the diffe...
Transaction in Own Shares
Transaction in Own Shares ICG Enterprise Trust plc (the “Company”) 21 November 2024 Transaction in Own Shares The Company announces that on 20 November 2024 it bought back 80,000 of its own shares, to be held as treasury shares, at an average price of 1230 pence per share. Further details are set out below: Number of shares held as treasury shares following settlement of this purchase: 8,275,308.Total shares in issue excluding treasury shares following settlement of this purchase: 64,637,692. The Company has bought back these shares under the authority granted by shareholders at its A...
Transaction in Own Shares
Transaction in Own Shares ICG Enterprise Trust plc (the “Company”) 20 November 2024 Transaction in Own Shares The Company announces that on 19 November 2024 it bought back 10,000 of its own shares, to be held as treasury shares, at an average price of 1236 pence per share. Further details are set out below: Number of shares held as treasury shares following settlement of this purchase: 8,195,308.Total shares in issue excluding treasury shares following settlement of this purchase: 64,717,692. The Company has bought back these shares under the authority granted by shareholders at its A...
Volta Finance Limited - Net Asset Value as at 31 October 2024
Volta Finance Limited - Net Asset Value as at 31 October 2024 Volta Finance Limited (VTA / VTAS)October 2024 monthly reportNOT FOR RELEASE, DISTRIBUTION, OR PUBLICATION, IN WHOLE OR PART, IN OR INTO THE UNITED STATES Guernsey, November 19th, 2024 AXA IM has published the Volta Finance Limited (the “Company” or “Volta Finance” or “Volta”) monthly report for October 2024. The full report is attached to this release and will be available on Volta’s website shortly (). Performance and Portfolio Activity Dear Investors, Volta Finance recorded a net performance of +4.3% in October bringing t...
Transaction in Own Shares
Transaction in Own Shares ICG Enterprise Trust plc (the “Company”) 19 November 2024 Transaction in Own Shares The Company announces that on 18 November 2024 it bought back 100,000 of its own shares, to be held as treasury shares, at an average price of 1250 pence per share. Further details are set out below: Number of shares held as treasury shares following settlement of this purchase: 8,185,308.Total shares in issue excluding treasury shares following settlement of this purchase: 64,727,692. The Company has bought back these shares under the authority granted by shareholders at its ...
Transaction in Own Shares
Transaction in Own Shares ICG Enterprise Trust plc (the “Company”) 18 November 2024 Transaction in Own Shares The Company announces that on 15 November 2024 it bought back 15,000 of its own shares, to be held as treasury shares, at an average price of 1251 pence per share. Further details are set out below: Number of shares held as treasury shares following settlement of this purchase: 8,085,308.Total shares in issue excluding treasury shares following settlement of this purchase: 64,827,692. The Company has bought back these shares under the authority granted by shareholders at its A...
- Pedro Fonseca
Apax Global Alpha - Transaction activity picked up in Q324
Apax Global Alpha (AGA) reported a Q324 NAV total return (TR) of 1.7% in euro terms on a constant currency basis (-0.2% including fx changes), with a 3.2pp positive contribution from earnings momentum across its private equity (PE) investments. The company experienced a pick-up in new investments, and also saw some positive trends on the realisation front. Following recent exits and accounting for the take-private transaction of Thoughtworks, AGA’s pro-forma exposure to listed holdings has been ...
Transaction in Own Shares
Transaction in Own Shares ICG Enterprise Trust plc (the “Company”) 15 November 2024 Transaction in Own Shares The Company announces that on 14 November 2024 it bought back 10,000 of its own shares, to be held as treasury shares, at an average price of 1250 pence per share. Further details are set out below: Number of shares held as treasury shares following settlement of this purchase: 8,070,308.Total shares in issue excluding treasury shares following settlement of this purchase: 64,842,692. The Company has bought back these shares under the authority granted by shareholders at its A...
Transaction in Own Shares
Transaction in Own Shares ICG Enterprise Trust plc (the “Company”) 14 November 2024 Transaction in Own Shares The Company announces that on 13 November 2024 it bought back 15,000 of its own shares, to be held as treasury shares, at an average price of 1252 pence per share. Further details are set out below: Number of shares held as treasury shares following settlement of this purchase: 8,060,308.Total shares in issue excluding treasury shares following settlement of this purchase: 64,852,692. The Company has bought back these shares under the authority granted by shareholders at its A...
Transaction in Own Shares
Transaction in Own Shares ICG Enterprise Trust plc (the “Company”) 13 November 2024 Transaction in Own Shares The Company announces that on 12 November 2024 it bought back 59,175 of its own shares, to be held as treasury shares, at an average price of 1257 pence per share. Further details are set out below: Number of shares held as treasury shares following settlement of this purchase: 8,045,308.Total shares in issue excluding treasury shares following settlement of this purchase: 64,867,692. The Company has bought back these shares under the authority granted by shareholders at its A...
Hardman & Co Q&A on ICG Enterprise Trust (ICGT): Operating companies’ ...
Hardman & Co Research Hardman & Co Q&A on ICG Enterprise Trust (ICGT): Operating companies’ widening margins and strong EBITDA growth 12-Nov-2024 / 12:15 GMT/BST The issuer is solely responsible for the content of this announcement. Analyst interview | Investment Companies Q&A on ICG Enterprise Trust (ICGT) | Operating companies’ widening margins and strong EBITDA growth ICG Enterprise Trust (ICGT) is the topic of conversation when Hardman & Co analyst Mark Thomas joins DirectorsTalk Interviews. Mark Thomas discusses the recent performance and strategic direction of ICG Ente...
Hardman & Co Video Event: Shield Therapeutics (STX) Investor Forum
Hardman & Co Research Hardman & Co Video Event: Shield Therapeutics (STX) Investor Forum 11-Nov-2024 / 14:00 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Video Event | Shield Therapeutics (STX) Investor Forum We are delighted to announce that Shield Therapeutics (STX) will be presenting at Hardman & Co's upcoming Investor Forum at 3:00pm this Thursday 14 November 2024. to secure your place and submit questions. A commercial-stage pharmaceutical company, Shield Therapeutics is strategically positioned to address the significant u...
Director Declaration
Director Declaration ICG Enterprise Trust plc (the “Company”) 5 November 2024 Director Declaration In accordance with the Financial Conduct Authority's Listing Rules, ICG Enterprise Trust plc announces that Adiba Ighodaro, Non-Executive Director of the Company, has been appointed as a non executive director of Polar Capital Technology Trust plc, effective from 3 December 2024. Analyst / Investor enquiries: Chris HuntShareholder Relations, ICG+44 (0) 20 3545 2020 Andrew LewisCompany Secretary, ICG+44 (0) 20 3545 1344 Media:Catherine Armstrong,Corporate Communications, ICG+44 (0) 20 3...
Transaction in Own Shares
Transaction in Own Shares ICG Enterprise Trust plc (the “Company”) 5 November 2024 Transaction in Own Shares The Company announces that on 4 November 2024 it bought back 15,000 of its own shares, to be held as treasury shares, at an average price of 1240 pence per share. Further details are set out below: Number of shares held as treasury shares following settlement of this purchase: 7,986,133.Total shares in issue excluding treasury shares following settlement of this purchase: 64,926,867. The Company has bought back these shares under the authority granted by shareholders at its Ann...
Volta Finance Limited - Director/PDMR Shareholding
Volta Finance Limited - Director/PDMR Shareholding Volta Finance Limited (VTA/VTAS) Notification of transactions by directors, persons discharging managerial responsibilities and persons closely associated with them NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES ***** Guernsey, 4 November 2024 Pursuant to the announcements made on 5 April 2019 and 26 June 2020 relating to changes to the payment of directors fees, Volta Finance Limited (the “Company” or “Volta”) has purchased 3,403 ordinary shares of no par value in the...
Q&A on Real Estate Credit Investments: Understanding the discount, its...
Hardman & Co Research Q&A on Real Estate Credit Investments: Understanding the discount, its rise, and future prospects 01-Nov-2024 / 12:00 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co analyst interview | Diversified Financial Services Q&A on Real Estate Credit Investments (RECI) | Understanding the discount, its rise, and future prospects Real Estate Credit Investments (RECI) Plc is the topic of conversation when Hardman & Co analyst Mark Thomas joins DirectorsTalk Interviews. In this interview, Mark provides insights into Real E...
- Mark Thomas
- Martin Hall
The Hardman & Co Monthly: November 2024
Feature article: “ROOM” (Running Out of Money) risk, How managing liquidity risk can sustain corporate value and maintain shareholder confidence As we come close to the end of a very challenging year for many UK entrepreneurs, as well as a frustrating period for shareholders, it is time to address one elephant in the ROOM! ROOM stands for “Running Out of Money”. The risk of doing so, or the perception that it could occur, can destroy corporate values and prematurely paralyse a business. While ...
Voting Rights and Capital
Voting Rights and Capital ICG Enterprise Trust plc (the “Company”) 1 November 2024 Voting Rights and Capital In accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1R the Company would like to notify the market of the following: At the close of business on the 31 October 2024, the Company had 72,913,000 Ordinary shares in issue, of which 7,961,133 were held in Treasury. Therefore, the total number of voting rights in the Company was 64,951,867.The above figure 65,106,867 may be used by Shareholders as the denominator for the calculations by which they will determine ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.